ClinicalTrials.gg
Active, not recruitingNCT06391710Updated Nov 24, 2025

HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

A Phase 2 interventional study of HRS9531 and Placebo in Heart Failure With Preserved Ejection Fraction, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, none of them phase 3. Heart Failure · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
2nd of 10
203 · median 69
Started
2024
with 1 other
Phase 2
3 of 10
2 open now
Registered
2nd of 10
by date

Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., this one is the 2nd largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 2, and was the 2nd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with preserved ejection fraction.

A total of 200 obese subjects with heart failure with preserved ejection fraction would be enrolled. Eligible subjects were randomly assigned to either HRS9531 group or placebo group and were treated with HRS9531 injection or placebo, respectively, for 52 weeks.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age above or equal to 18 years at the time of signing .
  2. (BMI) greater than or equal to 28.0 kg/m\^2
  3. (NYHA) Class II-IV;
  4. (LVEF) greater than or equal to 45 percentage at screening

Exclusion criteria

Exclusion Criteria:

  1. Medical history of myocardial infarction, acute decompensated heart failure, heart failure requiring hospitalization or urgent heart failure visit, unstable angina, stroke, or within 30 days prior to or at screening;
  2. (HbA1c) greater than or equal to 11.0% at screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    HRS9531

    Drug: HRS9531

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • subcutaneous

  • DrugPlacebo

    subcutaneous

06

What researchers measure

Primary outcomes

  1. Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score

    Time frame: From baseline (week 0) to week 36

  2. Change in body weight

    Time frame: From baseline (week 0) to week 36

Secondary outcomes

  1. Hierarchical composite of time to all-cause death

    Time frame: From baseline (week 0) to week 36,52

  2. Hierarchical composite of number of heart failure events requiring hospitalisation or urgent heart failure visit

    Time frame: From baseline (week 0) to week 36,52

  3. Hierarchical composite of time to the first heart failure events requiring hospitalisation or urgent heart failure visit

    Time frame: From baseline (week 0) to week 36,52

  4. Hierarchical composite of difference at least 5 in KCCQ clinical summary score change from baseline to 36, 52 weeks

    Time frame: From baseline (week 0) to week 36,52

  5. Change in KCCQ clinical summary score

    Time frame: From baseline (week 0) to week 52

  6. Change in body weight

    Time frame: From baseline (week 0) to week 52

  7. Change in C-Reactive Protein (CRP)

    Time frame: From baseline (week 0) to week 36,52

  8. Change in N-terminal pro-b-type natriuretic peptide (NT-proBNP)

    Time frame: From baseline (week 0) to week 36,52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jan 2026, 20 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 20 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Apr 30, 2024
StartActual
May 6, 2024
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06391710
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
May 6, 2024
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Nov 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion